BeiGene CEO Eyes Biologics Deals for New US Innovation Center in New Jersey

1. New Facility: BeiGene has opened a new biologics manufacturing and clinical research and development (R&D) facility in Hopewell, New Jersey, with an investment of $800 million.
2. Capacity: The facility spans 42 acres and has 400,000 square feet of production space, with the potential to expand and create hundreds of high-tech jobs by the end of 2025.
3. CEO's Goals: CEO John Oyler aims to leverage the facility's biologics know-how to search for deals, including in China, and to enhance the company's manufacturing and R&D capabilities in the US.
4. Pipeline: BeiGene has over 30 molecules in various stages of clinical and commercial development, including targeted degraders, antibody-drug conjugates, monoclonal antibodies, and traditional small molecules, which could combat 80% of the world's cancers.
5. Strategic Expansion: The new facility is part of BeiGene's strategy to lower costs, bolster supply chain resilience, and swiftly adapt to new innovative modalities.